Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers

Next Previous
Trial Profile

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMC R117C (Primary) ; Antineoplastics
  • Indications Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Immunocore

Most Recent Events

  • 17 Dec 2024 According to an Immunocore media release, company announced that the first patient has been treated in the Phase 1/2 trial of IMC-R117C in colorectal and other gastrointestinal cancers.
  • 17 Dec 2024 Status changed from planning to recruiting, according to an Immunocore media release.
  • 08 May 2024 According to an Immunocore media release, the CTA for IMC-R117C was accepted in April 2024 by the EMA, and the Company expects a Phase 1 clinical trial to start in the second half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top